Literature DB >> 12884069

Incidence and risk factors for nosocomial infections caused by fluoroquinolone-resistant Escherichia coli.

K Huotari1, E Tarkka, V Valtonen, E Kolho.   

Abstract

The aim of the retrospective case-control study presented here was to elucidate the incidence, risk factors, and outcomes of nosocomial infections caused by quinolone-resistant Escherichia coli (QREC). During the 3-year period studied, 51 nosocomial QREC infections were found, and the characteristics of these cases were compared with those of 102 control patients with quinolone-susceptible nosocomial infections. In the multivariate analysis, risk factors were identified as prior quinolone therapy (odds ratio [OR], 18.49; 95% confidence interval [CI], 5.53-61.82; P value <0.001), urinary tract abnormalities (OR, 6.69; 95% CI, 1.68-26.63; P=0.007), and prior therapy with other antimicrobial agents (OR, 3.57; 95% CI, 1.38-9.27; P=0.009). No difference in mortality or in length of hospital stay was found. Prudent use of quinolones, especially in patients with urinary tract abnormalities, is probably the best way to avoid an increase in the incidence of QREC infections, but further studies on interventions with restricted use of quinolones are necessary to demonstrate the effectiveness and safety of this strategy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12884069     DOI: 10.1007/s10096-003-0975-6

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Molecular epidemiology and evolution of resistance to quinolones in Escherichia coli after prolonged administration of ciprofloxacin in patients with prostatitis.

Authors:  Juan P Horcajada; Jordi Vila; Antonio Moreno-Martínez; Joaquim Ruiz; Jose Antonio Martínez; Miquel Sánchez; Eladio Soriano; Josep Mensa
Journal:  J Antimicrob Chemother       Date:  2002-01       Impact factor: 5.790

2.  Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences.

Authors:  J R Aparicio; J Such; S Pascual; A Arroyo; J Plazas; E Girona; A Gutiérrez; F de Vera; J M Palazón; F Carnicer; M Pérez-Mateo
Journal:  J Hepatol       Date:  1999-08       Impact factor: 25.083

3.  Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones.

Authors:  J Ena; M M López-Perezagua; C Martínez-Peinado; M A Cia-Barrio; I Ruíz-López
Journal:  Diagn Microbiol Infect Dis       Date:  1998-02       Impact factor: 2.803

4.  Emergence and dissemination of quinolone-resistant Escherichia coli in the community.

Authors:  J Garau; M Xercavins; M Rodríguez-Carballeira; J R Gómez-Vera; I Coll; D Vidal; T Llovet; A Ruíz-Bremón
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

5.  CDC definitions for nosocomial infections, 1988.

Authors:  J S Garner; W R Jarvis; T G Emori; T C Horan; J M Hughes
Journal:  Am J Infect Control       Date:  1988-06       Impact factor: 2.918

6.  Are quinolone-resistant uropathogenic Escherichia coli less virulent?

Authors:  Jordi Vila; Karine Simon; Joaquin Ruiz; Juan P Horcajada; Maria Velasco; Margarita Barranco; Antonio Moreno; Josep Mensa
Journal:  J Infect Dis       Date:  2002-09-13       Impact factor: 5.226

7.  Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli.

Authors:  J Ena; C Amador; C Martinez; V Ortiz de la Tabla
Journal:  J Urol       Date:  1995-01       Impact factor: 7.450

8.  Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures.

Authors:  L C McDonald; F J Chen; H J Lo; H C Yin; P L Lu; C H Huang; P Chen; T L Lauderdale; M Ho
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Low-level colonization and infection with ciprofloxacin-resistant gram-negative bacilli in a skilled nursing facility.

Authors:  Y L Lee; T Cesario; V McCauley; L Flionis; A Pax; L Thrupp
Journal:  Am J Infect Control       Date:  1998-12       Impact factor: 2.918

10.  An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project.

Authors:  G Kahlmeter
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

View more
  7 in total

1.  The clinical impact of fluoroquinolone resistance in patients with E coli bacteremia.

Authors:  Bernard C Camins; Jonas Marschall; Shannon R DeVader; Dawn E Maker; Matthew W Hoffman; Victoria J Fraser
Journal:  J Hosp Med       Date:  2011 Jul-Aug       Impact factor: 2.960

2.  Impact of antibiotic use during hospitalization on the development of gastrointestinal colonization with Escherichia coli with reduced fluoroquinolone susceptibility.

Authors:  Jennifer H Han; Warren B Bilker; Irving Nachamkin; Pam Tolomeo; Xiangqun Mao; Neil O Fishman; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2013-08-23       Impact factor: 3.254

3.  Spontaneous conversion to quinolone and fluoroquinolone resistance among wild-type Escherichia coli isolates in relation to phylogenetic background and virulence genotype.

Authors:  James R Johnson; Brian Johnston; Michael A Kuskowski; Raul Colodner; Raul Raz
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 4.  Antibiotic prophylaxis during chemotherapy-induced neutropenia for patients with acute leukemia.

Authors:  Sarah P Hammond; Lindsey R Baden
Journal:  Curr Hematol Malig Rep       Date:  2007-05       Impact factor: 4.213

5.  Risk factors for quinolone-resistant Escherichia coli infection: a systematic review and meta-analysis.

Authors:  Dong-Mei Zhu; Qiu-Hong Li; Yan Shen; Qin Zhang
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-09       Impact factor: 4.887

6.  Fluoroquinolone Can Be an Effective Treatment Option for Acute Pyelonephritis When the Minimum Inhibitory Concentration of Levofloxacin for the Causative Escherichia coli Is ≤16 mg/L.

Authors:  Yeonjae Kim; Bongyoung Kim; Seong Heon Wie; Jieun Kim; Moran Ki; Yong Kyun Cho; Seung Kwan Lim; Jin Seo Lee; Ki Tae Kwon; Hyuck Lee; Hee Jin Cheong; Dae Won Park; Seong Yeol Ryu; Moon Hyun Chung; Hyunjoo Pai
Journal:  Antibiotics (Basel)       Date:  2021-01-02

Review 7.  Evaluation of the health and healthcare system burden due to antimicrobial-resistant Escherichia coli infections in humans: a systematic review and meta-analysis.

Authors:  M C MacKinnon; J M Sargeant; D L Pearl; R J Reid-Smith; C A Carson; E J Parmley; S A McEwen
Journal:  Antimicrob Resist Infect Control       Date:  2020-12-10       Impact factor: 4.887

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.